Flu cases surge across US. See where cases are rising.

U.S. flu activity has surged to 'high' nationwide, with 8% of medical visits influenza-related the week ending Dec. 27, a 48% week-over-week jump in hospitalizations and about 120,000 hospitalizations and 5,000 deaths so far this season. CDC data show ~33% test positivity that week (23,350 of 70,757 tests), wastewater surveillance reported a 146% increase in median viral concentration in December, and genomic surveillance finds H3N2 caused 91% of tested cases with 90.5% of those being the mutated subclade K, which may reduce—but not eliminate—vaccine effectiveness. Investors should note potential localized impacts on labor supply, healthcare demand and consumer-facing sectors, but the story currently poses limited direct macro market disruption.

Analysis

Market structure: Rapid rise (48% week/week hospitalizations; 8% of visits flu-related) reallocates near-term demand toward diagnostics, retail pharmacies, PPE and antivirals while pressuring elective-care and health-insurer margins. Winners: rapid-test makers, pharmacy chains and vaccine manufacturers preparing next-season formulations; losers: elective-surgery dependent hospitals and short-duration insurers facing higher claim frequency. Competitive dynamics favor high-velocity, margin-rich rapid antigen/POC test suppliers (greater pricing power for QDEL-like players) and incumbent vaccine manufacturers with manufacturing capacity (SNY/GSK).

Risk assessment: Tail risk is a vaccine-escape scenario where hospitalizations >2x current runs, causing constrained ICU capacity and urgent policy actions (price controls, emergency procurement) within 4–8 weeks. Short-term (days–weeks) demand shocks amplify working-capacity issues (staffing, supply chain for antivirals/PPE); medium-term (3–9 months) uncertainty centers on strain selection for next season; long-term (12–24 months) outcome hinges on mRNA vaccine adoption. Hidden dependencies include CDC sequencing cadence (weekly) and WHO strain recommendations (Feb–Mar) that will re-price vaccine/biotech exposure.

Trade implications: Tactical long exposure to diagnostics (QDEL) and lab services (DGX, LH) for 1–3 month revenue tail; 2–4% allocation to pharmacy retailers (CVS, WMT) for OTC/shot volumes immediate 4–8 week payoff. Pair trade: long QDEL, short UNH (dollar-neutral) for 3 months to capture testing/revenue vs insurer margin pressure; options: buy 3-month call spreads on QDEL and 3-month puts on UNH to asymmetrically express the view.

Contrarian angles: Consensus underweights mRNA upside—small, optional 1% position in MRNA for 12–24 month asymmetric payoff if mRNA flu shows >20% incremental VE improvement and forces market share shift. Beware that retail uplift may be front-loaded and already priced; limit retailer exposure to 2–4% and use tight stop-losses if CDC positivity drops below 15% nationally over two consecutive weeks.

Key Decisions for Investors

• Establish a 2–3% long position in QuidelOrtho (QDEL) sized to portfolio volatility, with intent to hold 1–3 months; complement with a 3-month call spread (buy ATM, sell ATM+10%) to limit capital and target 30–60% ROI if testing demand stays elevated (>25% test positivity weekly).
• Add a 2% long in CVS Health (CVS) or Walgreens (WBA) to capture pharmacy/OTC and vaccine-administering revenue over the next 4–8 weeks; trim to zero if CDC national influenza-like illness (ILI) visits fall below 5% for two consecutive weeks.
• Initiate a dollar-neutral pair trade: long QDEL (or DGX exposure) and short UnitedHealth (UNH) equal-dollar for 3 months to exploit increased testing/hospital revenue vs insurer margin pressure; hedge tail-risk with 3-month UNH puts (5–10% notional).
• Allocate 2% across SNY and GSK (1% each) as 6–12 month thematic vaccine reweighting ahead of Feb–Mar strain-selection guidance; increase to 4% if CDC sequencing shows subclade K >90% of isolates in two consecutive weeks.
• Establish a 1% long in Moderna (MRNA) as long-dated optionality (12–24 months) bet on mRNA flu efficacy; exit or double down if clinical readouts show >20% VE improvement versus egg-based vaccines or if regulatory pathway shortens.